Home 
FOR AUTHORS Bratislava Medical Journal 2018 Bratislava Medical Journal Vol.119, No.4, p.198-200, 2018
FOR AUTHORS Bratislava Medical Journal 2018 Bratislava Medical Journal Vol.119, No.4, p.198-200, 2018
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.119, No.4, p.198-200, 2018 |
||
| Title: Canakinumab as monotherapy for treatment of familial Mediterranean fever – first report in Central and Eastern Europe region | ||
| Author: M. Jesenak, K. Hrubiskova, L. Kapustova, M. Kostkova, P. Banovcin | ||
| Abstract: Autoinflammatory disorders (AID) are characterized by spontaneous attacks of acute inflammation with a broad spectrum of clinical symptoms. Ongoing inflammation and reoccurrence of acute flares can lead to the development of amyloidosis. One group of AID is represented by monogenic periodic fever syndromes while familial Mediterranean fever (FMF) is the most common form of AID from this group. Its prevalence in Central and Eastern Europe was reported to be very low. We report a case of FMF patient with a very severe clinical course of FMF and intolerance to colchicine, which is a gold standard for FMF treatment. The clinical effect of the application of anakinra was insufficient and accompanied with side effects and low tolerability. Switching to canakinumab (human monoclonal antibody against IL-1β) at dose of 150 mg every 4 weeks induced a rapid remission of the disease activity and inflammatory markers. However, due to relapse of acute flares after three weeks from application, the escalation of dose to 300 mg every 4 weeks induced a complete remission of symptoms and significantly improved the quality of life. This is the first report of successful canakinumab administration in FMF patient in Central and Eastern Europe, a region with very low incidence of FMF (Tab. 1, Ref. 16). |
||
| Keywords: autoinflammation, monogenic periodic fever syndromes, familial Mediterranean fever, amyloidosis, colchicine-resistant disease, canakinumab | ||
| Published online: 09-Apr-2018 | ||
| Year: 2018, Volume: 119, Issue: 4 | Page From: 198, Page To: 200 | |
| doi:10.4149/BLL_2018_036 |
||
|
|
 download file |
|